InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-24 | 2026-02-26 | Sachetta Eric | Director | Purchase | 2,000 | $3.81 | $8K | 142.1K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenues | $27.5M-34.3% | $41.8M+71.3% | $24.4M-45.2% | $44.5M |
| Cost of sales | $15.6M-10.1% | $17.4M+68.0% | $10.3M-30.6% | $14.9M |
| Gross profit | $11.9M-51.4% | $24.4M+73.8% | $14.1M-52.5% | $29.6M |
| General and administrative | $7.9M+10.2% | $7.1M+38.6% | $5.2M+3.0% | $5.0M |
| Selling and marketing | $6.5M+31.0% | $5.0M-11.2% | $5.6M-11.4% | $6.3M |
| Research and development | $7.8M+84.5% | $4.2M+14.6% | $3.7M+6.3% | $3.5M |
| Total operating expenses | $22.2M+35.7% | $16.3M+13.1% | $14.4M-2.4% | $14.8M |
| (Loss) income from operations | -$10.3M-227.4% | $8.1M | — | — |
| Interest income, net | $683K-26.7% | $932K-6.0% | $992K+161.1% | $380K |
| Other income, net | $683K-26.7% | $932K-9.9% | $1.0M-92.1% | $13.2M |
| (Loss) income before income taxes | -$9.6M-206.7% | $9.0M | — | — |
| (Benefit from) provision for income taxes | -$1.9M-180.2% | $2.4M | — | — |
| Net (loss) income | -$7.7M-216.1% | $6.6M | — | — |
| Net (loss) income per share - basic | -$470-214.6% | $410 | — | — |
| Net (loss) income per share - diluted | -$470-214.6% | $410 | — | — |
| Weighted average number of shares used in computing net (loss) income per share - basic | $16.33B+0.1% | $16.31B | — | — |
| Weighted average number of shares used in computing net (loss) income per share - diluted | $16.33B-0.2% | $16.36B | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Sensus Healthcare Q1 Earnings Call Highlights
Sensus Healthcare Announces Amicable Resolution of Commercial Dispute with SkinCure Oncology
Sensus outlines full year profitability goal for 2026 as new CPT codes take effect
Sensus Healthcare, Inc. (SRTS) Q1 2026 Earnings Call Transcript